BioCentury | Aug 31, 2018
Clinical News

Pfizer ends Phase II trials of DMD candidate

...rights to the anti-MSTN adnectin from Bristol-Myers Squibb Co. (NYSE:BMY) (see “BMS, Roche Deal” ). Milo Biotechnology LLC...
BioCentury | Aug 30, 2018
Clinical News

Pfizer ends Phase II trials of DMD candidate

...anti-MSTN adnectin from Bristol-Myers Squibb Co. (NYSE:BMY) (see “BMS Out-Licenses Programs to Biogen, Roche” ). Milo Biotechnology LLC...
BioCentury | Feb 2, 2018
Product Development

AA Viral meme

...BCIQ: BioCentury Online Intelligence, ClinicalTrials.gov Company Product Indication Transgene Route of administration Dose Status AAV1 Milo Biotechnology LLC...
BioCentury | Sep 26, 2016
Financial News

Milo Biotechnology completes venture financing

Milo Biotechnology LLC , Cleveland, Ohio Business: Musculoskeletal Date completed: 2016-09-20 Type: Venture financing Raised: Not disclosed Investors: JumpStart Inc.; Rev1 Ventures Note: The amount raised is not disclosed. WIR Staff...
BioCentury | Jul 23, 2015
Tools & Techniques

Gene therapy's coming of age

...Muscle Phase II AmpliPhi Biosciences Corp. (OTCBB:APHB); Applied Genetic Technologies Corp. (NASDAQ:AGTC); Celladon Corp. (NASDAQ:CLDN); Milo Biotechnology LLC...
...clinical development: Advantagene Inc. , Ascend Biopharmaceuticals Ltd. , Etubics Corp. , GenVec Inc. , Milo Biotechnology LLC...
BioCentury | Oct 27, 2014
Clinical News

AAV1-FS344: Phase I/IIa data

...product has Orphan Drug designation to treat Becker and Duchenne muscular dystrophy in the U.S. Milo Biotechnology LLC...
BioCentury | Dec 17, 2012
Clinical News

AAV1-FS344 regulatory update

...dystrophy and inclusion body myositis. The product is in preclinical testing for Duchenne muscular dystrophy. Milo Biotechnology LLC...
BioCentury | Aug 6, 2012
Emerging Company Profile

Milo: Dismissing dystrophin

...Cambridge, Mass. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Asklepios BioPharmaceutical Inc. , Chapel Hill, N.C. Milo Biotechnology LLC...
...the Netherlands Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Summit Corp. plc (LSE:SUMM), Abingdon, U.K. Sidebars Milo Biotechnology LLC...
BioCentury | Feb 20, 2012
Financial News

Milo Biotechnology completes venture financing

Milo Biotechnology LLC , Cleveland, Ohio Business: Musculoskeletal Date completed: 2/14/12 Type: Venture financing Raised: $250,000 Investor: JumpStart Inc. WIR Staff Musculoskeletal...
BioCentury | Feb 17, 2012
Company News

Newco Milo debuts to develop muscular dystrophy treatment

Milo Biotechnology LLC (Cleveland, Ohio) raised $250,000 in seed funding from the not-for-profit JumpStart Inc. The newco's lead product, AAV1-FS, is an adeno-associated virus (AAV) vector used to deliver follistatin. Follistatin is a protein that...
Items per page:
1 - 10 of 10
BioCentury | Aug 31, 2018
Clinical News

Pfizer ends Phase II trials of DMD candidate

...rights to the anti-MSTN adnectin from Bristol-Myers Squibb Co. (NYSE:BMY) (see “BMS, Roche Deal” ). Milo Biotechnology LLC...
BioCentury | Aug 30, 2018
Clinical News

Pfizer ends Phase II trials of DMD candidate

...anti-MSTN adnectin from Bristol-Myers Squibb Co. (NYSE:BMY) (see “BMS Out-Licenses Programs to Biogen, Roche” ). Milo Biotechnology LLC...
BioCentury | Feb 2, 2018
Product Development

AA Viral meme

...BCIQ: BioCentury Online Intelligence, ClinicalTrials.gov Company Product Indication Transgene Route of administration Dose Status AAV1 Milo Biotechnology LLC...
BioCentury | Sep 26, 2016
Financial News

Milo Biotechnology completes venture financing

Milo Biotechnology LLC , Cleveland, Ohio Business: Musculoskeletal Date completed: 2016-09-20 Type: Venture financing Raised: Not disclosed Investors: JumpStart Inc.; Rev1 Ventures Note: The amount raised is not disclosed. WIR Staff...
BioCentury | Jul 23, 2015
Tools & Techniques

Gene therapy's coming of age

...Muscle Phase II AmpliPhi Biosciences Corp. (OTCBB:APHB); Applied Genetic Technologies Corp. (NASDAQ:AGTC); Celladon Corp. (NASDAQ:CLDN); Milo Biotechnology LLC...
...clinical development: Advantagene Inc. , Ascend Biopharmaceuticals Ltd. , Etubics Corp. , GenVec Inc. , Milo Biotechnology LLC...
BioCentury | Oct 27, 2014
Clinical News

AAV1-FS344: Phase I/IIa data

...product has Orphan Drug designation to treat Becker and Duchenne muscular dystrophy in the U.S. Milo Biotechnology LLC...
BioCentury | Dec 17, 2012
Clinical News

AAV1-FS344 regulatory update

...dystrophy and inclusion body myositis. The product is in preclinical testing for Duchenne muscular dystrophy. Milo Biotechnology LLC...
BioCentury | Aug 6, 2012
Emerging Company Profile

Milo: Dismissing dystrophin

...Cambridge, Mass. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Asklepios BioPharmaceutical Inc. , Chapel Hill, N.C. Milo Biotechnology LLC...
...the Netherlands Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Summit Corp. plc (LSE:SUMM), Abingdon, U.K. Sidebars Milo Biotechnology LLC...
BioCentury | Feb 20, 2012
Financial News

Milo Biotechnology completes venture financing

Milo Biotechnology LLC , Cleveland, Ohio Business: Musculoskeletal Date completed: 2/14/12 Type: Venture financing Raised: $250,000 Investor: JumpStart Inc. WIR Staff Musculoskeletal...
BioCentury | Feb 17, 2012
Company News

Newco Milo debuts to develop muscular dystrophy treatment

Milo Biotechnology LLC (Cleveland, Ohio) raised $250,000 in seed funding from the not-for-profit JumpStart Inc. The newco's lead product, AAV1-FS, is an adeno-associated virus (AAV) vector used to deliver follistatin. Follistatin is a protein that...
Items per page:
1 - 10 of 10